Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
93% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ROSG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ROSG' s 10-Year Cash to Debt Range
Min: 0.77  Med: 74.83 Max: No Debt
Current: No Debt
Equity to Asset 0.87
ROSG's Equity to Asset is ranked higher than
89% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ROSG: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
ROSG' s 10-Year Equity to Asset Range
Min: -0.27  Med: 0.70 Max: 0.95
Current: 0.87
-0.27
0.95
Interest Coverage No Debt
ROSG's Interest Coverage is ranked higher than
84% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. ROSG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ROSG' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -3.85
M-Score: -32.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1074.00
ROSG's Operating margin (%) is ranked lower than
92% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. ROSG: -1074.00 )
Ranked among companies with meaningful Operating margin (%) only.
ROSG' s 10-Year Operating margin (%) Range
Min: -9864.67  Med: -4550.20 Max: -1074
Current: -1074
-9864.67
-1074
Net-margin (%) -1094.65
ROSG's Net-margin (%) is ranked lower than
92% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. ROSG: -1094.65 )
Ranked among companies with meaningful Net-margin (%) only.
ROSG' s 10-Year Net-margin (%) Range
Min: -11003.33  Med: -5245.51 Max: -1094.65
Current: -1094.65
-11003.33
-1094.65
ROE (%) -74.40
ROSG's ROE (%) is ranked lower than
79% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. ROSG: -74.40 )
Ranked among companies with meaningful ROE (%) only.
ROSG' s 10-Year ROE (%) Range
Min: -545.27  Med: -84.49 Max: -47.3
Current: -74.4
-545.27
-47.3
ROA (%) -67.22
ROSG's ROA (%) is ranked lower than
79% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. ROSG: -67.22 )
Ranked among companies with meaningful ROA (%) only.
ROSG' s 10-Year ROA (%) Range
Min: -286.59  Med: -81.74 Max: -40.87
Current: -67.22
-286.59
-40.87
ROC (Joel Greenblatt) (%) -283.45
ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. ROSG: -283.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ROSG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1823.73  Med: -1074.53 Max: -199.41
Current: -283.45
-1823.73
-199.41
Revenue Growth (3Y)(%) -15.70
ROSG's Revenue Growth (3Y)(%) is ranked lower than
79% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ROSG: -15.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ROSG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -15.7
Current: -15.7
EBITDA Growth (3Y)(%) -55.00
ROSG's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ROSG: -55.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ROSG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -41.60 Max: -4.6
Current: -55
EPS Growth (3Y)(%) -55.40
ROSG's EPS Growth (3Y)(%) is ranked lower than
94% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ROSG: -55.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ROSG' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.9  Med: -30.40 Max: 45.9
Current: -55.4
-68.9
45.9
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.89
ROSG's P/B is ranked higher than
72% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ROSG: 1.89 )
Ranked among companies with meaningful P/B only.
ROSG' s 10-Year P/B Range
Min: 0.73  Med: 1.81 Max: 4.84
Current: 1.89
0.73
4.84
P/S 20.50
ROSG's P/S is ranked lower than
87% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ROSG: 20.50 )
Ranked among companies with meaningful P/S only.
ROSG' s 10-Year P/S Range
Min: 3.33  Med: 63.82 Max: 209.09
Current: 20.5
3.33
209.09
Current Ratio 7.44
ROSG's Current Ratio is ranked higher than
86% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ROSG: 7.44 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s 10-Year Current Ratio Range
Min: 0.65  Med: 6.49 Max: 25.08
Current: 7.44
0.65
25.08
Quick Ratio 7.44
ROSG's Quick Ratio is ranked higher than
89% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ROSG: 7.44 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s 10-Year Quick Ratio Range
Min: 0.65  Med: 6.49 Max: 25.08
Current: 7.44
0.65
25.08
Days Sales Outstanding 92.97
ROSG's Days Sales Outstanding is ranked lower than
75% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. ROSG: 92.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s 10-Year Days Sales Outstanding Range
Min: 38.98  Med: 126.39 Max: 885.73
Current: 92.97
38.98
885.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.94
ROSG's Price/Net Cash is ranked higher than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. ROSG: 4.94 )
Ranked among companies with meaningful Price/Net Cash only.
ROSG' s 10-Year Price/Net Cash Range
Min: 1.31  Med: 2.63 Max: 7.58
Current: 4.94
1.31
7.58
Price/Net Current Asset Value 2.00
ROSG's Price/Net Current Asset Value is ranked higher than
90% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. ROSG: 2.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ROSG' s 10-Year Price/Net Current Asset Value Range
Min: 1.14  Med: 1.64 Max: 5.01
Current: 2
1.14
5.01
Price/Tangible Book 1.89
ROSG's Price/Tangible Book is ranked higher than
81% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. ROSG: 1.89 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s 10-Year Price/Tangible Book Range
Min: 1.02  Med: 1.57 Max: 3.68
Current: 1.89
1.02
3.68
Price/Median PS Value 0.32
ROSG's Price/Median PS Value is ranked higher than
92% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ROSG: 0.32 )
Ranked among companies with meaningful Price/Median PS Value only.
ROSG' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.02 Max: 2.49
Current: 0.32
0.21
2.49
Earnings Yield (Greenblatt) (%) -73.16
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. ROSG: -73.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -73.16  Med: 56.40 Max: 2915.2
Current: -73.16
-73.16
2915.2

Analyst Estimate

Dec15 Dec16
EPS($) -0.95 -0.80
EPS without NRI($) -0.95 -0.80

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Receives Conditional Approval from New York State for Lung Biomarker Aug 06 2015
Rosetta Genomics Receives Accreditation from College of American Pathologists for its Laboratory in... Aug 06 2015
Rosetta Genomics Expands High-Value Molecular Diagnostic Offering with Launch of OncoGxSelect™ Jul 28 2015
ROSG: Strong Revenue Growth Expected for 1H15 and the Full Year 2015 Jul 09 2015
Rosetta Genomics Files Pro Forma Financials in Connection with PersonalizeDx Acquisition Jul 08 2015
Rosetta Genomics Announces Participation in Cantor Fitzgerald’s Inaugural “From Bench to... Jul 01 2015
Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services Jun 16 2015
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake Jun 01 2015
Rosetta Genomics Launches OncoGxOne™ May 28 2015
Rosetta Genomics Announces Selection of First Pilot Project Grant under Strategic Alliance with... May 26 2015
Rosetta Genomics Launches Two Assays for Bladder Cancer May 14 2015
Rosetta Genomics Receives Additional U.S. Patent Protection for the Cancer Origin Test™ May 13 2015
Data on Rosetta Genomics’ Novel Thyroid Nodule Classification Assay to be Presented at the... May 12 2015
Rosetta Genomics’ Patent on Therapeutic Use of miR-34a Upheld by European Patent Office in... Apr 29 2015
Rosetta Genomics Announces Data Published in Leukemia Research Apr 20 2015
Rosseta Genomics (ROSG) Stock Continues To Climb Today on Analyst Upgrade Apr 17 2015
Rosetta Genomics Shares Upgraded At Cantor Apr 17 2015
Rosetta Genomics (ROSG) Stock is Spiking on Receipt of Cancer Origin Test Patent Apr 16 2015
Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay Apr 16 2015
ROSG: Acquisition of PersonalizeDx Will Accelerate Substantial Revenue Growth Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK